Abstract:G protein-coupled receptors (GPCRs) as the most important class of pharmacological targets regulate G-protein and β-arrestin-mediated signaling through allosteric interplay, which are responsible for different biochemical and physiological actions like therapeutic efficacy and side effects. However, the allosteric mechanism underlying preferentially recruiting one transducer versus the other has been poorly understood, limiting drug design. Motivated by this issue, we utilize accelerated molecular dynamics simulation coupled with potential of mean force (PMF), molecular mechanics Poisson Boltzmann surface area (MM/PBSA) and protein structure network (PSN) to study two ternary complex systems of a representative class A GPCR (μ-opioid receptor (μOR)) bound by an agonist and one specific transducer (G-protein and β-arrestin). The results show that no significant difference exists in the whole structure of μOR between two transducer couplings, but displays transducer-dependent changes in the intracellular binding region of μOR, where the β-arrestin coupling results in a narrower crevice with TM7 inward movement compared with the G-protein. In addition, both the G-protein and β-arrestin coupling can increase the binding affinity of the agonist to the receptor. However, the interactions between the agonist and μOR also exhibit transducer-specific changes, in particular for the interaction with ECL2 that plays an important role in recruiting β-arrestin. The allosteric network analysis further indicates that Y1483.33, F1523.37, F1563.41, N1914.49, T1603.45, Y1062.42, W2936.48, F2896.44, I2485.54 and Y2525.58 play important roles in equally activating G-protein and β-arrestin. In contrast, M1613.46 and R1653.50 devote important contributions to preferentially recruit G-protein while D1643.49 and R179ICL2 are revealed to be important for selectively activating β-arrestin. The observations provide useful information for understanding the biased activation mechanism.

Agonist-selective activation of individual G-proteins by muscarinic receptors

Single Hormone or Synthetic Agonist Induces Gs/Gi Coupling Selectivity of EP Receptors Via Distinct Binding Modes and Propagating Paths.

Importance of receptor expression in the classification of novel ligands at the M2 muscarinic acetylcholine receptor

Design of allosteric modulators that change GPCR G protein subtype selectivity

Structure-based Discovery of Selective Positive Allosteric Modulators of Antagonists for the M2 Muscarinic Acetylcholine Receptor.

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

Positive allosteric modulation of a GPCR ternary complex

Distinct Structural Changes in a G Protein-coupled Receptor Caused by Different Classes of Agonist Ligands

Muscarinic Receptors and Related Selective Drugs: Research Advances

Design, Synthesis, and Biological Evaluation of 4,4’-Difluorobenzhydrol Carbamates as Selective M1 Antagonists

An Allosteric Ligand Stabilizes Distinct Conformations in the M2 Muscarinic Acetylcholine Receptor

Muscarinic Acetylcholine Receptor Modulators Derived from Natural Toxins and Diverse Interaction Modes

Structural and dynamic insights into supra-physiological activation and allosteric modulation of a muscarinic acetylcholine receptor

Structure and dynamics determine G protein coupling specificity at a class A GPCR

The optimization of a novel selective antagonist for human M<sub>2</sub> muscarinic acetylcholine receptor

Molecular Insights into the Allosteric Coupling Mechanism Between an Agonist and Two Different Transducers for Μ-Opioid Receptors.

Characterization of Gα and Gα activation by catechol and non-catechol dopamine D1 receptor agonists

Synthesis and Biological Characterization of 1-Methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole Derivatives As Muscarinic Agonists for the Treatment of Neurological Disorders

Functional selectivity and dualsteric/bitopic GPCR targeting

Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembrane interface